Medtronic Launches China Fund II to Accelerate Local Healthcare Innovation and Expand Strategic Ecosystem

On April 25, Medtronic, a global medical technology company based in Shanghai, announced the launch of a new venture capital fund focused on the Chinese market—the Medtronic China Phase II Fund. Guided by the demands of the local healthcare market, the fund aims to accelerate the clinical adoption of innovative products from Chinese medtech startups through investment and incubation, thereby benefiting more patients in China and worldwide. Meanwhile, it will help Medtronic further integrate into the local healthcare innovation ecosystem and create potential new opportunities for technological innovation within both Medtronic and China’s medical industry.

This is the second venture capital fund established by Medtronic in China, following its inaugural fund in 2016. China is also the only market globally where Medtronic has set up a dedicated regional venture capital fund.

Zhang Xi, Deputy Director of the Shanghai Pilot Free Trade Zone Administrative Committee and Director of the Waigaoqiao Bonded Zone Administration; Yang Chao, Member of the Standing Committee of the Pudong New Area District Committee of the Communist Party of China and Deputy District Mayor of Pudong New Area; Jeff Massa, Chairman and Chief Executive Officer of Medtronic; and Gu Yushao, Senior Vice President of Medtronic and President of Greater China, attended the launch ceremony of Medtronic China Phase II Fund in Shanghai.

 From left to right: Gu Yushao, Senior Vice President and President of Greater China at Medtronic; Zhang Xi, Deputy Director of the Shanghai Free Trade Zone Administrative Committee and Director of the Bonded Zone Administration Bureau; Jeff Marrazzo, Chairman and Chief Executive Officer of Medtronic; Yang Chao, Member of the Standing Committee of the Pudong New Area District Committee of the Communist Party of China and Deputy District Mayor of Shanghai’s Pudong New Area

In his on-site address, Jeff Marrazzo, Chairman and CEO of Medtronic, stated that Medtronic is continuously leveraging cutting-edge technological breakthroughs to accelerate innovation in disease prevention, diagnosis, and treatment. However, the complexity of the challenges facing the global healthcare system means that no single company can realize this vision alone; it requires collaborative efforts from all industry players, regardless of size. The Medtronic China Phase II Fund will provide a platform for such collaborative models.

 Medtronic Chairman and CEO Jeff Massa

Following the establishment of Medtronic China Phase II Fund, it will focus on local medical technology innovation enterprises in early and mid-stage development. Leveraging Medtronic’s industry advantages, the fund will provide comprehensive post-investment management support to portfolio companies while creating potential opportunities for Medtronic to expand its product portfolio in the future. The fund will deeply explore frontier medical technologies such as digital health, artificial intelligence, and robotics, investing in diagnostic and therapeutic products related to major diseases including cardiovascular, neurological, and oncological conditions.

Gu Yushao, Senior Vice President of Medtronic and President of Greater China, stated, “Medtronic remains optimistic about the potential of healthcare innovation in China. Supporting and participating in local medical technology innovation in China is a vital component of our global strategy to foster healthcare innovation across all active markets. As the saying goes, ‘A long journey is achieved by steady steps, and the vast ocean embraces all rivers.’ Through the platform of the Medtronic China Phase II Fund, we hope to collaborate with more Chinese entrepreneurs to overcome critical challenges in medical technology, jointly serving the extensive patient populations in China and around the world.”

Prior to the official launch of Medtronic China Phase II Fund, Medtronic China Fund had been in operation for seven years and, together with Medtronic, invested in 10 Chinese startups across fields such as surgical robotics, neuromodulation, and ENT.